Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.54 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.47 |
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 5/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094174 | 0.79 | PDGFRB (0.55) | MKNK2 | |
| SCHEMBL6091767 | 0.77 | ACMSD (0.47) | — | |
| SCHEMBL6093061 | 0.76 | MKNK1 (0.56) | MKNK1MKNK2KMOABCB1CYP11B1 | |
| SCHEMBL6040654 | 0.76 | TNFRSF1A (0.52) | — | |
| SCHEMBL31591513 | 0.76 | MKNK1 (0.78) | MKNK1MKNK2KMOABCB1CYP11B1 | |
| SCHEMBL6040652 | 0.75 | AR (0.43) | MKNK1MKNK2 | |
| SCHEMBL1308012 | 0.74 | TUBB4A (0.64) | MKNK1MKNK2ABCB1ABCC1 | |
| SCHEMBL6040694 | 0.74 | CA2 (0.52) | MKNK1MKNK2ABCB1CYP11B1CYP11B2 | |
| SCHEMBL6091816 | 0.73 | TNFRSF1A (0.55) | ACLY | |
| SCHEMBL208351 | 0.73 | MKNK1 (1.00) | MKNK1MKNK2KMOGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | claimed |
| WO-2006004903-A2 | 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ATHEROGENICS, INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006004903-A2 | 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ATHEROGENICS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | MKNK1 4361/4885MKNK2 4286/4885KMO 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.